Interim results of the phase IV JAKoMo trial, a prospective, non-interventional study of symptoms and quality of life in myelofibrosis patients receiving ruxolitinib therapy

被引：0

作者：

Wehrle, J. ^{[1
]}

Geer, T. ^{[2
]}

Brudler, O. ^{[3
]}

Schaefer, E. ^{[4
]}

Tesch, H. ^{[5
]}

Cavanna, D. ^{[6
]}

Bachhuber, P. ^{[6
]}

Markhauser, M. ^{[6
]}

Koschmieder, S. ^{[7
]}

Mesa, R. A. ^{[8
]}

Pahl, H. L. ^{[1
]}

机构：

[1] Uniklin Freiburg, Sekt Mol Hamatol, Innere Med Hamatol Onkol & Stammzelltransplantat, Freiburg, Germany

[2] Diakonie Klinikum, Med Klin 3, Stuttgart, Germany

[3] Hamatol Onkol Praxis Brudler Heinrich Bangerter, Augsburg, Germany

[4] Onkol Schwerpunktpraxis, Bielefeld, Germany

[5] Onkol Gemeinschaftspraxis Bethanien Krankenhaus, Frankfurt, Germany

[6] Novartis Pharma GmbH, Nurnberg, Germany

[7] Uniklin RWTH, Fak Med, Klin Hamatol Onkol Hamostaseol & SZT, Aachen, Germany

[8] Mayo Clin, Ctr Canc, Div Hematol & Med Oncol, Scottsdale, AZ USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P757

引用

页码：227 / 228

页数：2